1. ICH guidelines, Q1A (R2): Stability Testing of New Drug Substances and Products (revision 2), International Conference on Harmonization. Available from: 〈http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm128204.pdf〉, 2003.
2. Available guidance and best practices for conducting forced degradation studies;Reynolds;Pharm. Technol.,2002
3. How to approach a forced degradation study;Brummer;Life Sci. Technol. Bull.,2011
4. FDA Guidance for Industry, INDs for Phase II and III Studies—Chemistry, Manufacturing, and Controls Information, Food and Drug Administration. Available from: 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070567.pdf〉, 2003.
5. FDA Guidance for Industry, INDs for Phase 2 and 3 Studies of Drugs, Including Specified Therapeutic Biotechnology-Derived Products, Draft Guidance, Food and Drug Administration. Available from: 〈http://www.fda.gov/ohrms/dockets/98fr/990674gd.pdf〉, 1999.